Pidilite is India’s favourite glue merchant, the reason every desi carpenter asks “Fevicol hai kya?” instead of “Adhesive hai kya?”. With a ₹1.59 lakh crore market cap and a stock P/E north of 72, investors are paying Bollywood star fees for a company that sells the chemical equivalent of haldi-doodh for broken furniture. Fevicol ads were funny, but the valuation is funnier.
2. Introduction
Pidilite is that rare FMCG-chemicals hybrid which managed to do what most brands only dream of—become a verb. Nobody says “adhesive,” they say “Fevicol lagao.” That’s market capture straight out of a brand strategy textbook.
But while customers pay ₹20 for Fevikwik at a kirana shop, investors are happily paying 16x book value and 11.8x sales. Why? Because Pidilite has convinced Dalal Street that selling glue is as premium as selling iPhones.
Let’s face it—half the reason people trust Pidilite is because of the decades of hilarious ads where elephants were glued to trucks. The other half is the distribution: 4,800 distributors and 2 lakh retailers. It’s harder to escape Fevicol in India than your nosy relatives during shaadi season.
Still, the ₹3,128 stock price comes with its own “Fevikwik moment”—blinking twice before sticking your money. The company has strong fundamentals, yes, but is it sticky enough at 72x earnings? Or is it just another case of “Dil bole Fevicol se” while portfolio returns cry “Elmer’s Glue se bhi sasta hota”?
3. Business Model – WTF Do They Even Do?
Pidilite is basically the IIT topper of adhesives. 53% of revenues come from adhesives and sealants (Fevicol, Fevikwik, M-Seal, Araldite). Then comes construction & paint chemicals (20%) with brands like Dr. Fixit and Roff—basically the stuff builders use to hide cracks before monsoon.
The B2C Consumer & Bazaar division (80% of revenues) makes it the HUL of chemicals. The B2B side (20%) deals with industrial resins and pigments—boring, but pays the bills.
The fun part? Their craft and hobby products like Fevicryl and Hobby Ideas—making school kids’ charts look colourful since Doordarshan era. Honestly, this is diversification desi parents can approve: “Padhai bhi karo, art & craft bhi karo.”
So the model is simple—sell sticky products for every possible situation. Broken chair? Fevicol. Leaking terrace? Dr. Fixit. School project? Fevicryl. Emergency jugaad? Fevikwik. If there’s a problem in India, Pidilite probably has a tube for it.
Question for you: Which Pidilite product have you personally abused the most? Fevicol on your bed, or Fevikwik on your slippers?
4. Financials Overview
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue (₹ Cr)
3,753
3,395
3,141
10.5%
19.5%
EBITDA (₹ Cr)
941
812
632
15.9%
48.9%
PAT (₹ Cr)
678
571
428
18.7%
58.4%
EPS (₹)
13.22
11.15
8.30
18.6%
59.2%
Annualised EPS = 13.22 × 4 = ₹52.9 Current P/E = 3,128 ÷ 52.9 = 59x (slightly better than the scary 72x, but still Dalal Street premium).
Commentary: That’s a very healthy YoY growth, but let’s be honest—any company that can get EBITDA to stick like this deserves respect. The only problem? Investors are already pricing Pidilite like it’s building Apple-style moats, when in reality it’s building waterproof moats with Dr. Fixit.
5. Valuation – Fair Value Range Only
P/E Method: Industry PE = 32. Pidilite is trading at 59x. Fair value EPS band = ₹52.9 × (35–45) = ₹1,851 – ₹2,380
EV/EBITDA Method: EV = ₹1,59,275 Cr. TTM EBITDA = ₹3,138 Cr. EV/EBITDA = 50.8x (vs sector avg ~20x). Fair value = Scale down = ₹1,250 – ₹2,000
DCF Method (8% growth, 10% WACC, 20-year horizon): Fair value comes around ₹2,000 – ₹2,400
Fair Value Range (blended): ₹1,700 – ₹2,400 CMP = ₹3,128. Translation: investors are paying Fevicol premium + nostalgia tax.
Disclaimer: This fair value range is for educational purposes only and is not investment advice.
6. What’s Cooking – News, Triggers, Drama
Pidilite has been spending ₹800 Cr on 29 capacity expansion projects (11 Greenfield, 18 Brownfield). Basically, building more factories to stick more things together.
Management musical chairs: Bharat Puri exits as MD, Sudhanshu Vats takes over with Kavinder Singh as Joint MD. Corporate gossip alert: whenever Pidilite
